Physiologic Blood Flow Is Turbulent
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Radionuclear Measurement of Peripheral Hemodynamics In
RadionuclearMeasurementof Peripheral Hemodynamics in Selection of Vasodilators for Treatment of Heart Failure Yasuhiro Todo, Mitsumasa Ohyanagi, Ryu Fujisue, and Tadaaki Iwasaki Hyogo College ofMedicine, Nishinomiya, Japan Inorder to select the optimal vasodilator for the treatment of patients with congestive heart failure (CHF), the acute effects of three vasodilators (isosorbide dinitrate (ISDN) 5 mg, nifedipine 10 mg, and prazosin 1 mg) on peripheral capacitance and resistance vessels (CV and RV)were evaluated by a newly devised radionuclear technique (Study 1).Thirty-six @ patients with chronic CHF were dividedinto Group A (ejectionfraction (EF) 35%, n = 20, mean EF: 47.2 ±6.5%) and B (EF < 35%, n = 16, mean EF: 24.8 ±7.1%). ISDNproduced the strongest CVdilatation(25% in both groups). Nifedipinereduced RVtone in Groups A and B (14% and 27%, respectively),and CVtone in Group A (6%). Prazosin had the most prominent effects on both vessels in Group B. From these results, it appeared: (a) ISDN is indicated for the cases with increased CV tone, (b) nifedipine is suitable for those with @ increased RV tone, (C)in cases of increased tone in both vessels, nifedipine (when EF 35%) or prazosin (when EF < 35%) is optimal.To evaluate the validityof this assignment, 49 subjects with CHF were divided into Group 1 (n = 16, increased CV tone), Group 2 (n = 17, increased RV tone), and Group 3 (n = 16, increased CV and RV tone) in Study 2. In Group 1, the changes of all indexes were not significantly different between the subjects treated with optimal drug based on the assignment (subgroup P) and those with a non-optimaldrug (subgroup N)after 2 wk of therapy. -
Relationship Between Vasodilatation and Cerebral Blood Flow Increase in Impaired Hemodynamics: a PET Study with the Acetazolamide Test in Cerebrovascular Disease
CLINICAL INVESTIGATIONS Relationship Between Vasodilatation and Cerebral Blood Flow Increase in Impaired Hemodynamics: A PET Study with the Acetazolamide Test in Cerebrovascular Disease Hidehiko Okazawa, MD, PhD1,2; Hiroshi Yamauchi, MD, PhD1; Hiroshi Toyoda, MD, PhD1,2; Kanji Sugimoto, MS1; Yasuhisa Fujibayashi, PhD2; and Yoshiharu Yonekura, MD, PhD2 1PET Unit, Research Institute, Shiga Medical Center, Moriyama, Japan; and 2Biomedical Imaging Research Center, Fukui Medical University, Fukui, Japan Key Words: acetazolamide; cerebrovascular disease; cerebral The changes in cerebral blood flow (CBF) and arterial-to- blood volume; vasodilatory capacity; cerebral perfusion pressure capillary blood volume (V0) induced by acetazolamide (ACZ) are expected to be parallel each other in the normal circula- J Nucl Med 2003; 44:1875–1883 tion; however, it has not been proven that the same changes in those parameters are observed in patients with cerebro- vascular disease. To investigate the relationship between changes in CBF, vasodilatory capacity, and other hemody- namic parameters, the ACZ test was performed after an The ability of autoregulation to maintain the cerebral 15O-gas PET study. Methods: Twenty-two patients with uni- blood flow (CBF), which resides in the cerebral circulation lateral major cerebral arterial occlusive disease underwent despite transient changes in systemic mean arterial blood 15 PET scans using the H2 O bolus method with the ACZ test pressure, has been shown to occur via the mechanism of 15 after the O-gas steady-state method. CBF and V0 for each arteriolar vasodilatation in the cerebral circulation (1). The subject were calculated using the 3-weighted integral vasodilatory change in the cerebral arteries is assumed for method as well as the nonlinear least-squares fitting method. -
Introduction to Biofluid Mechanics Portonovo S
To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only by the author(s), editor(s), reviewer(s), Elsevier and typesetter TNQ Books and Journals Pvt Ltd. It is not allowed to publish this proof online or in print. This proof copy is the copyright property of the publisher and is confidential until formal publication. CHAPTER 16 Introduction to Biofluid Mechanics Portonovo S. Ayyaswamy OUTLINE 16.1 Introduction e2 Exercises e71 16.2 The Circulatory System in the Acknowledgments e72 Human Body e2 Literature Cited e72 16.3 Modeling of Flow in Blood Vessels e18 Supplemental Reading e73 16.4 Introduction to the Fluid Mechanics of Plants e65 CHAPTER OBJECTIVES • To properly introduce the subject of biofluid • To review the parametric impact of the prop- mechanics including the necessary language erties of rigid, flexible, branched, and curved fl • To describe the components of the human cir- tubes on blood ow culation system and document their nominal • To provide an overview of fluid transport in characteristics plants • To present analytical results of relevant models of steady and pulsatile blood flow Fluid Mechanics http://dx.doi.org/10.1016/B978-0-12-405935-1.00016-2 e1 Copyright © 2016 Elsevier Inc. All rights reserved. To protect the rights of the author(s) and publisher we inform you that this PDF is an uncorrected proof for internal business use only by the author(s), editor(s), reviewer(s), Elsevier and typesetter TNQ Books and Journals Pvt Ltd. It is not allowed to publish this proof online or in print. -
Hemodynamic Effects of Vasodilators and Long-Term Response in Heart Failure
JACC Vol. 3, No.6 1521 June 1984:1521-30 REPORTS ON THERAPY Hemodynamic Effects of Vasodilators and Long-Term Response in Heart Failure JOSEPH A. FRANCIOSA, MD, FACC, W. BRUCE DUNKMAN, MD, FACC,* CHERYL L. LEDDY, MD* Philadelphia, Pennsylvania and Little Rock, Arkansas Hemodynamic responses to vasodilators are commonly ml/min per kg (p < 0.01), and exercise duration also assessed when starting long-term vasodilator treatment increased by 1.8 ± 3.5 minutes (p < 0.01). Changes in in patients with chronic left ventricular failure, although maximal oxygen uptake, however, did not correlate with the relation between short- and long-term responses is short-term changes in pulmonary wedge pressure (cor• not established. Thus, short- and long-term hemody• relation coefficient [r] = - 0.14), cardiac index (r = namic responses to placebo and vasodilators (isosorbide - 0.01) or systemic vascular resistance (r = - 0.20). dinitrate, minoxidil and enalapril or captopril) were Long-term hemodynamic changes also failed to correlate measured and long-term clinical efficacy was assessed with changes in exercise capacity. Baseline hemody• by changes in exercise capacity after 1 to 5 months of namics, cardiac dimensions and left ventricular ejection vasodilator administration (plus digitalis and diuretic fraction before vasodilator administration all failed to agents) in 46 patients with New York Heart Association correlate with baseline exercise capacity or with long• fun~tional class II to IV heart failure caused by cardio• term changes in exercise capacity. myopathy. There were no significant changes in hemo• Thus, hemodynamic measurements at initiation or dynamics or exercise capacity during placebo treatment. -
Medical Management of Advanced Heart Failure
CLINICAL CARDIOLOGY CLINICIAN’S CORNER Medical Management of Advanced Heart Failure Anju Nohria, MD Context Advanced heart failure, defined as persistence of limiting symptoms de- Eldrin Lewis, MD spite therapy with agents of proven efficacy, accounts for the majority of morbidity and mortality in heart failure. Lynne Warner Stevenson, MD Objective To review current medical therapy for advanced heart failure. EART FAILURE HAS EMERGED AS Data Sources We searched MEDLINE for all articles containing the term advanced a major health challenge, in- heart failure that were published between 1980 and 2001; EMBASE was searched from creasing in prevalence as age- 1987-1999, Best Evidence from 1991-1998, and Evidence-Based Medicine from 1995- adjusted rates of myocardial 1999. The Cochrane Library also was searched for critical reviews and meta-analyses Hinfarction and stroke decline.1 Affect- of congestive heart failure. ing 4 to 5 million people in the United Study Selection Randomized controlled trials of therapy for 150 patients or more States with more than 2 million hospi- were included if advanced heart failure was represented. Other common clinical situ- talizations each year, heart failure alone ations were addressed from smaller trials as available, trials of milder heart failure, con- accounts for 2% to 3% of the national sensus guidelines, and both published and personal clinical experience. health care budget. Developments her- Data Extraction Data quality was determined by publication in peer-reviewed lit- alded in the news media increase pub- erature or inclusion in professional society guidelines. lic expectations but focus on decreas- Data Synthesis A primary focus for care of advanced heart failure is ongoing iden- ing disease progression in mild to tification and treatment of the elevated filling pressures that cause disabling symp- moderate stages2,3 or supporting the cir- toms. -
Chapter 9 Monitoring of the Heart and Vascular System
Chapter 9 Monitoring of the Heart and Vascular System David L. Reich, MD • Alexander J. Mittnacht, MD • Martin J. London, MD • Joel A. Kaplan, MD Hemodynamic Monitoring Cardiac Output Monitoring Arterial Pressure Monitoring Indicator Dilution Arterial Cannulation Sites Analysis and Interpretation Indications of Hemodynamic Data Insertion Techniques Systemic and Pulmonary Vascular Resistances Central Venous Pressure Monitoring Frank-Starling Relationships Indications Monitoring Coronary Perfusion Complications Electrocardiography Pulmonary Arterial Pressure Monitoring Lead Systems Placement of the Pulmonary Artery Catheter Detection of Myocardial Ischemia Indications Intraoperative Lead Systems Complications Arrhythmia and Pacemaker Detection Pacing Catheters Mixed Venous Oxygen Saturation Catheters Summary References HEMODYNAMIC MONITORING For patients with severe cardiovascular disease and those undergoing surgery associ- ated with rapid hemodynamic changes, adequate hemodynamic monitoring should be available at all times. With the ability to measure and record almost all vital physi- ologic parameters, the development of acute hemodynamic changes may be observed and corrective action may be taken in an attempt to correct adverse hemodynamics and improve outcome. Although outcome changes are difficult to prove, it is a rea- sonable assumption that appropriate hemodynamic monitoring should reduce the incidence of major cardiovascular complications. This is based on the presumption that the data obtained from these monitors are interpreted correctly and that thera- peutic decisions are implemented in a timely fashion. Many devices are available to monitor the cardiovascular system. These devices range from those that are completely noninvasive, such as the blood pressure (BP) cuff and ECG, to those that are extremely invasive, such as the pulmonary artery (PA) catheter. To make the best use of invasive monitors, the potential benefits to be gained from the information must outweigh the potential complications. -
Hemodynamic Parameters in the Assessment of Fluid Status in A
PERIOPERATIVE MEDICINE ABSTRACT Background: Measuring fluid status during intraoperative hemorrhage is challenging, but detection and quantification of fluid overload is far more diffi- cult. Using a porcine model of hemorrhage and over-resuscitation, it is hypoth- Hemodynamic Parameters esized that centrally obtained hemodynamic parameters will predict volume status more accurately than peripherally obtained vital signs. in the Assessment Methods: Eight anesthetized female pigs were hemorrhaged at 30 ml/min to a blood loss of 400 ml. After each 100 ml of hemorrhage, vital signs (heart of Fluid Status in a rate, systolic blood pressure, mean arterial pressure, diastolic blood pressure, pulse pressure, pulse pressure variation) and centrally obtained hemodynamic Porcine Hemorrhage and parameters (mean pulmonary artery pressure, pulmonary capillary wedge pressure, central venous pressure, cardiac output) were obtained. Blood Resuscitation Model volume was restored, and the pigs were over-resuscitated with 2,500 ml of crystalloid, collecting parameters after each 500-ml bolus. Hemorrhage Eric S. Wise, M.D., Kyle M. Hocking, Ph.D., and resuscitation phases were analyzed separately to determine differences Monica E. Polcz, M.D., Gregory J. Beilman, M.D., among parameters over the range of volume. Conformity of parameters during Colleen M. Brophy, M.D., Jenna H. Sobey, M.D., hemorrhage or over-resuscitation was assessed. Philip J. Leisy, M.D., Roy K. Kiberenge, M.D., Bret D. Alvis, M.D. Results: During the course of hemorrhage, changes from baseline euvolemia were observed in vital signs (systolic blood pressure, diastolic blood pressure, ANESTHESIOLOGY 2021; 134:607–16 and mean arterial pressure) after 100 ml of blood loss. -
A Brief History of Arterial Blood Flow—From Harvey and Newton to Computational Analysis
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector CLINICAL RESEARCH STUDIES From the Southern Association for Vascular Surgery Presidential address: A brief history of arterial blood flow—from Harvey and Newton to computational analysis Joseph P. Archie, Jr, PhD, MD, Raleigh, NC My education and interests have always pointed toward ships, and of fluids moving through vessels, like arterial fluid mechanics both as a researcher and as a clinical vascu- blood flow. The basis of solving these problems lies in lar surgeon trying to restore or maintain arterial blood accurately determining fluid flow patterns near solid walls. flow. In 1970 to 1971 I was a research fellow at the These problems are defined by physical laws represented Cardiovascular Research Institute of the University of by differential equations that have been known for cen- California Medical Center, San Francisco. The director of turies. Computational analysis, a numerical method of the Institute, Julius Comroe, wrote a small book entitled solving these equations, was developed years ago, awaiting Retrospectroscope: Insights Into Medical Discovery,1 in which the advent of high-speed computers to do the work. he makes a strong case for basic science research leading to When pulsatile flow in an arterial segment is smooth unexpected important findings, as opposed to targeted and undisturbed, the probability of myointimal hyperpla- research. The first correct description of human circulation sia, thrombosis, or atherosclerosis developing is low. The was given almost 400 years ago by William Harvey. During converse is true in segments that have disturbed flow. -
Pulsatile Blood Flow in a Pipe
Computers & Fluids Vol. 27, No. 3, pp. 367±380, 1998 # 1998 Elsevier Science Ltd. All rights reserved Printed in Great Britain PII: S0045-7930(97)00041-8 0045-7930/98 $19.00 + 0.00 PULSATILE BLOOD FLOW IN A PIPE GIUSEPPE PONTRELLI1 1Istituto per le Applicazioni del Calcolo (CNR), Viale del Policlinico, 137, 00161 Rome, Italy (Received 13 January 1997; revised 18 January 1997) AbstractÐThe unsteady ¯ow of blood in a straight, long, rigid pipe, driven by an oscillatory pressure gradient is studied. Three dierent non±newtonian models for blood are considered and compared. One of them turns out to oer the best ®t of experimental data, when the rheological parameters are suit- ably ®xed. Numerical results are obtained by a spectral collocation method in space and the implicit trapezoidal ®nite dierence method in time. # 1998 Elsevier Science Ltd. All rights reserved 1. INTRODUCTION The desire to understand the ¯ow of blood through the cardiovascular system and prosthetic devices has stimulated a lot of research activity in hemodynamics. Such studies are of particular importance because there is indirect evidence that the cause and the developments of many car- diovascular diseases are, to a great extent, related to the characteristics of blood ¯ow, such as the high values of the shear stress at the wall or its variation [1±4]. The study of the rheological properties of blood can allow a better understanding of blood circulation. The latter depends on numerous factors such as the driving force of the heart, the shape, as well as mechanical and physiological behaviour of the vascular walls [1,5±8]. -
Cerebral Hemodynamics During Cerebral Ischemia Induced by Acute Hypotension
Cerebral Hemodynamics during Cerebral Ischemia Induced by Acute Hypotension Frank A. Finnerty Jr., … , Lloyd Witkin, Joseph F. Fazekas J Clin Invest. 1954;33(9):1227-1232. https://doi.org/10.1172/JCI102997. Research Article Find the latest version: https://jci.me/102997/pdf CEREBRAL HEMODYNAMICS DURING CEREBRAL ISCHEMIA INDUCED BY ACUTE HYPOTENSION 1 BY FRANK A. FINNERTY, JR., LLOYD WITKIN, AND JOSEPH F. FAZEKAS WITH THE TECHNICAL ASSISTANCE OF MARIE LANGBART AND WILLIAM K. YOUNG (From the Department of Medicine, Georgetown University School of Medicine and the George- town and George Washington Medical Divisions, District of Columbia General Hospital, Washington, D. C.) (Submitted for publication February 1, 1954; accepted May 20, 1954) The extreme dependence of the brain upon its seven patients with malignant hypertension. In seven circulation for substrates essential for the main- subjects, the mean arterial pressure was reduced sig- nificantly below normal but not to the extent of inducing tenance of its metabolic activity is well recognized. signs of cerebral ischemia. Five patients with spontane- A cessation of the cerebral circulation for only a ous postural hypotension were also studied. few minutes, as occurs in cardiac arrest, results in Control studies were obtained after the subject had been irreversible brain damage. The brain, for the most tilted (head up) 30 to 40 degrees for a period of at least part, is an aerobic organ and its large oxygen de- 30 minutes. The subjects in the drug-induced hypo- tension group were then given a 1 per cent solution of mands probably account for its unusual suscepti- hexamethonium 2 intravenously at a rate of 1 mg. -
Persistent Hemodynamic Benefits of Cardiac Resynchronization
View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Journal of the American College of Cardiology Vol. 53, No. 7, 2009 © 2009 by the American College of Cardiology Foundation ISSN 0735-1097/09/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.08.079 Cardiac Resynchronization Therapy Persistent Hemodynamic Benefits of Cardiac Resynchronization Therapy With Disease Progression in Advanced Heart Failure Wilfried Mullens, MD, Tanya Verga, RN, Richard A. Grimm, DO, FACC, Randall C. Starling, MD, MPH, FACC, Bruce L. Wilkoff, MD, FACC, W. H. Wilson Tang, MD, FACC Cleveland, Ohio Objectives Our aim was to determine the potential hemodynamic contributions of cardiac resynchronization therapy (CRT) in patients admitted for advanced decompensated heart failure. Background CRT restores synchrony of the heart resulting in hemodynamic support that can facilitate the reversal of left ven- tricular (LV) remodeling in some patients. Methods A total of 40 consecutive patients with advanced decompensated heart failure and CRT implanted Ͼ3 months, admitted due to hemodynamic derangements, underwent simultaneous comprehensive echocardiographic and invasive hemodynamic evaluation under different CRT settings. Results All patients (mean LV ejection fraction 22 Ϯ 7%, LV end-diastolic volume 323 Ϯ 140 ml, 40% ischemic) had experienced progressive cardiac remodeling despite adequate LV lead positions and continuous biventricular pacing. A significant worsening of hemodynamics was observed immediately when CRT was programmed OFF in the majority (88%) of patients (systolic blood pressure: 105 Ϯ 12 mm Hg to 98 Ϯ 13 mm Hg; pulmonary capil- lary wedge pressure: 17 Ϯ 6mmHgto21Ϯ 7 mm Hg; cardiac output: 4.6 Ϯ 1.4 l/min·m2 to 4.0 Ϯ 1.1 l/min·m2; all p Ͻ 0.001). -
Clinical and Research Considerations
Journal of Cardiac Failure Vol. 22 No. 8 2016 Consensus Statement Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group SEAN P. COLLINS, MD, MSc,1,* PHILLIP D. LEVY, MD, MPH,2 JENNIFER L. MARTINDALE, MD,3 MARK E. DUNLAP, MD,4 ALAN B. STORROW, MD,1 PETER S. PANG, MD, MSc,5 NANCY M. ALBERT, RN, PhD,6 G. MICHAEL FELKER, MD, MS,7 GREGORY J. FERMANN, MD,8 GREGG C. FONAROW, MD,9 MICHAEL M. GIVERTZ, MD,10 JUDD E. HOLLANDER, MD,11 DAVID J. LANFEAR, MD,12 DANIEL J. LENIHAN, MD,13 JOANN M. LINDENFELD, MD,13 W. FRANK PEACOCK, MD,14 DOUGLAS B. SAWYER, MD, PhD,15 JOHN R. TEERLINK, MD,16 AND JAVED BUTLER, MD, MPH, MBA17 Nashville, Tennessee; Detroit, Michigan; New York and Long Island, New York; Cleveland and Cincinnati, Ohio; Indianapolis, Indiana; Raleigh-Durham, North Carolina; Los Angeles and San Francisco, California; Boston, Massachusetts; Philadelphia, Pennsylvania; Houston, Texas; and Portland, Maine ABSTRACT Management approaches for patients in the emergency department (ED) who present with acute heart failure (AHF) have largely focused on intravenous diuretics. Yet, the primary pathophysiologic derangement un- derlying AHF in many patients is not solely volume overload. Patients with hypertensive AHF (H-AHF) represent a clinical phenotype with distinct pathophysiologic mechanisms that result in elevated ventricu- lar filling pressures. To optimize treatment response and minimize adverse events in this subgroup, we propose that clinical management be tailored to a conceptual model of disease based on these mechanisms.